Glutathione — The Master Antioxidant

Glutathione (GSH) is a small tripeptide — just gamma-glutamate, cysteine, and glycine — but it is the single most important antioxidant molecule in human cells. Intracellular concentration runs 3-10 millimolar, dwarfing every other antioxidant by orders of magnitude (Vitamin C is in the micromolar range). It is the substrate for glutathione peroxidase that neutralizes hydrogen peroxide and lipid peroxides, the substrate for the glutathione-S-transferase family that conjugates electrophilic toxins for excretion, the maintainer of protein and Vitamin C and E in their reduced forms, the cysteine reservoir for the liver, and the upstream control point for cellular redox status. Glutathione depletion is now recognized as a unifying feature of aging and nearly every chronic disease. This deep-dive walks through the biochemistry, the validated lab tests for status, the disappointing oral-glutathione bioavailability story, and the supplements (liposomal, S-acetyl, NAC plus glycine) that actually raise tissue levels.

Table of Contents

  1. What Glutathione Is and Why It Dominates Cellular Antioxidant Defense
  2. Synthesis: The Two-Step ATP-Dependent Pathway
  3. The GSH/GSSG Redox Couple as Cellular Status Indicator
  4. Enzymatic Functions: GPx, GST, Glutaredoxin
  5. Detoxification: Phase II Conjugation and the Liver
  6. The Oral Glutathione Bioavailability Problem
  7. Supplements That Actually Raise Tissue Glutathione
  8. Conditions Associated with Glutathione Depletion
  9. Lab Testing for Glutathione Status
  10. Cautions and Drug Interactions
  11. Key Research Papers
  12. Connections

What Glutathione Is and Why It Dominates Cellular Antioxidant Defense

Glutathione is a tripeptide composed of three amino acids joined in an unusual way: gamma-glutamate — cysteine — glycine. The "gamma" linkage between glutamate and cysteine (using the gamma-carboxyl group of glutamate rather than the standard alpha-carboxyl) makes glutathione resistant to digestion by most peptidases — an evolutionary feature that protects intracellular glutathione from rapid breakdown but also creates the oral-bioavailability problem discussed below.

The functional group that does the antioxidant work is the thiol (-SH) group on the cysteine residue. This thiol readily donates an electron to neutralize reactive oxygen species and reactive electrophiles. When two glutathione molecules each donate an electron, they form a disulfide bond between their cysteine sulfurs, producing oxidized glutathione (GSSG). The GSSG is then recycled back to two GSH molecules by glutathione reductase using NADPH (generated by the pentose phosphate pathway) as the electron donor.

Three properties make glutathione the dominant cellular antioxidant:

  1. Sheer concentration — 3-10 mM intracellular, with liver hepatocytes at the top of that range. By comparison, intracellular Vitamin C is ~1-5 mM in adrenal medulla and brain (the highest tissues) and far less elsewhere; Vitamin E is in the membrane micromolar range. Glutathione's mass abundance means it can absorb large oxidant loads without depletion.
  2. Versatile chemistry — the thiol can directly reduce peroxides (with GPx), conjugate electrophiles (with GST), reduce disulfides on oxidatively damaged proteins (glutaredoxin system), and recycle oxidized Vitamin C and Vitamin E back to their active reduced forms. No other antioxidant has this functional breadth.
  3. Regenerable — unlike Vitamin C and E, which the body cannot synthesize de novo, glutathione is synthesized inside every cell continuously, and the oxidized form is recycled rather than excreted.

This makes glutathione the cellular currency of antioxidant capacity. When researchers talk about "the master antioxidant," this is not marketing — it is biochemistry.

Back to Table of Contents

Synthesis: The Two-Step ATP-Dependent Pathway

Glutathione is synthesized in two sequential ATP-dependent enzyme steps:

  1. Step 1 (rate-limiting): gamma-glutamyl cysteine ligase (GCL, formerly called gamma-glutamylcysteine synthetase) joins glutamate to cysteine, forming gamma-glutamyl-cysteine. This step consumes ATP. GCL is composed of a catalytic subunit (GCLC) and a modifier subunit (GCLM), both transcriptionally regulated by Nrf2. Cysteine is the rate-limiting substrate in most physiological conditions — cellular cysteine availability determines synthesis rate, which is why NAC (N-acetylcysteine) is the most effective glutathione-boosting supplement.
  2. Step 2: glutathione synthetase (GSS) adds glycine to the dipeptide, completing the tripeptide. This step also consumes ATP. GSS is not normally rate-limiting except in the rare inborn error glutathione synthetase deficiency.

The pathway requires three precursor amino acids, four cofactors, and energy:

Practical implication: a supplementation strategy targeting glutathione should include cysteine (NAC), glycine, selenium, and adequate B-vitamin status — not just oral glutathione capsules.

Back to Table of Contents

The GSH/GSSG Redox Couple as Cellular Status Indicator

The ratio of reduced to oxidized glutathione (GSH/GSSG) is the most accurate single biochemical indicator of cellular redox status. In healthy resting cells the ratio is approximately 100:1 (overwhelmingly reduced). Under oxidative stress the ratio drops — first to 50:1, then 25:1, and in severe oxidative stress to 10:1 or below.

The redox potential of the GSH/GSSG couple can be calculated from the Nernst equation and the measured concentrations. In healthy cytoplasm the redox potential is approximately -240 to -250 mV. As GSSG accumulates this becomes less negative (toward -200 mV in oxidatively stressed cells, -170 mV in apoptotic cells). The shift in redox potential triggers downstream signaling: at -240 mV the cell proliferates normally; at -210 mV the cell halts division and enters quiescence; at -180 mV the cell triggers apoptosis. Glutathione is therefore not just a buffer absorbing ROS — it is a redox signal that the cell reads to decide whether to grow, rest, or die.

Different organelles maintain different redox potentials. The endoplasmic reticulum is intentionally more oxidizing than the cytoplasm (around -180 mV) because disulfide bond formation in nascent proteins requires an oxidizing environment. Mitochondrial matrix is approximately -280 mV (more reducing than cytoplasm, supporting electron transport chain function). The nucleus tracks closely with cytoplasm. When measuring glutathione in research or clinical settings, the compartment matters — whole-cell glutathione obscures these important compartmental differences.

Back to Table of Contents

Enzymatic Functions: GPx, GST, Glutaredoxin

Glutathione almost never acts alone — it is the substrate for three major enzyme families that direct its antioxidant chemistry to specific targets.

Glutathione peroxidases (GPx, 8 family members) — selenoproteins that use glutathione to reduce hydrogen peroxide to water, and lipid hydroperoxides to their corresponding alcohols. GPx1 is the major cytosolic form, GPx4 is specialized for membrane lipid peroxides (and is the enzyme inhibited in ferroptosis cell death), GPx2 is gut-specific, GPx3 is plasma-secreted. Selenium deficiency impairs all of them — this is why selenium and glutathione status must be considered together.

Glutathione-S-transferases (GST, 6 cytosolic families plus microsomal forms) — conjugate glutathione to electrophilic molecules (drug metabolites, environmental toxins, carcinogens). The glutathione conjugate is then processed through the mercapturic acid pathway and excreted in urine. This is the dominant Phase II detoxification mechanism for compounds like acetaminophen reactive metabolite NAPQI, naphthalene, vinyl chloride, ethylene oxide, and hundreds of others. GST polymorphisms (GSTM1 null, GSTT1 null) are common (40-60% of populations) and associated with altered chemical sensitivity and cancer risk.

Glutaredoxin (Grx) system — uses glutathione to reduce protein disulfides that form on oxidatively damaged proteins, restoring native protein structure. Especially important in protein folding quality control and in repairing oxidatively damaged thioredoxin (which has its own NADPH-dependent reduction system in parallel).

Recycling of other antioxidants — glutathione directly reduces the tocopheryl radical (oxidized Vitamin E) back to Vitamin E, and reduces the ascorbyl radical (oxidized Vitamin C) back to Vitamin C. This is why glutathione, Vitamin C, and Vitamin E are inseparable as a functional network rather than independent antioxidants.

Back to Table of Contents

Detoxification: Phase II Conjugation and the Liver

The liver is the body's primary detoxification organ and has the highest glutathione concentration of any tissue (~8-10 mM in healthy hepatocytes). Liver detoxification proceeds in three phases:

  1. Phase I (cytochrome P450 oxidation) — CYP450 enzymes add oxygen or hydroxyl groups to lipophilic xenobiotics, making them more water-soluble but often more reactive (sometimes more toxic, as with acetaminophen).
  2. Phase II conjugation — the reactive Phase I product is conjugated to a polar carrier molecule. The main pathways are glucuronidation (UGT enzymes), sulfation (SULT enzymes), glycine conjugation, methylation (with SAMe), acetylation (NAT enzymes), and glutathione conjugation (GST enzymes). The glutathione conjugate is then processed through the mercapturic acid pathway.
  3. Phase III excretion — ABC transporters pump the conjugated metabolite into bile (for fecal excretion) or back to plasma for urinary excretion.

The classic clinical example is acetaminophen overdose. Acetaminophen is normally cleared 90% by glucuronidation and sulfation; only 5-10% goes through CYP2E1, generating the reactive intermediate NAPQI which is immediately quenched by glutathione conjugation. In overdose, glucuronidation and sulfation saturate, more acetaminophen flows through CYP2E1, NAPQI production exceeds glutathione capacity, hepatic glutathione drops below 30% of normal, free NAPQI then arylates hepatocyte proteins, and centrilobular necrosis ensues. The antidote is N-acetylcysteine (NAC) given to replenish hepatic glutathione — the same NAC discussed in the NAC deep-dive page.

Chronic environmental and dietary toxicant load (heavy metals, pesticides, industrial chemicals, mycotoxins) similarly draws on glutathione. Individuals with high toxicant exposure or impaired detoxification (GST polymorphisms, MTHFR variants affecting B-vitamin status) deplete glutathione faster and benefit more from supportive supplementation.

Back to Table of Contents

The Oral Glutathione Bioavailability Problem

For decades the supplement industry has sold oral glutathione capsules as a way to raise tissue glutathione. The biochemistry has always been skeptical: oral glutathione faces three problems.

  1. Digestive degradation — gamma-glutamyl transpeptidase in the intestinal brush border cleaves glutathione into its constituent amino acids before absorption. Most ingested glutathione never enters the bloodstream intact.
  2. First-pass hepatic extraction — any glutathione that does survive digestion is largely extracted by the liver on first pass through the portal circulation.
  3. Cell membrane impermeability — even if glutathione reached peripheral tissues intact, the cell membrane has no efficient glutathione transporter for uptake. Cells synthesize glutathione intracellularly rather than importing it.

The Allen and Bradley 2011 study and several follow-ups confirmed that conventional oral glutathione (500 mg/day for 4 weeks) does not raise blood or tissue glutathione in healthy adults. A more optimistic 2015 study by Richie et al. using 1000 mg/day for 6 months did show modest increases in some glutathione pools, suggesting prolonged high-dose use may eventually produce a measurable effect, possibly through providing cysteine after digestion rather than through intact glutathione delivery.

The practical takeaway is that oral conventional glutathione is, at best, an expensive way to deliver cysteine to the liver. There are more effective approaches.

Back to Table of Contents

Supplements That Actually Raise Tissue Glutathione

The interventions with the best evidence for actually raising tissue glutathione, ranked by quality of evidence:

  1. N-acetylcysteine (NAC) 600-1800 mg/day — supplies the rate-limiting cysteine precursor. Approved as Mucomyst for acetaminophen overdose, where it demonstrably restores depleted hepatic glutathione. Best-studied supplemental approach. See the NAC deep-dive.
  2. GlyNAC (glycine + NAC combination, often 100 mg/kg each per day) — Sekhar's Baylor group showed glycine is co-rate-limiting with cysteine in older adults. Their pilot trial in older adults showed restoration of erythrocyte glutathione to youthful levels, plus improvements in mitochondrial function, insulin sensitivity, and walking speed.
  3. Liposomal glutathione (typically 500-1000 mg/day) — encapsulating glutathione in phospholipid liposomes protects it through digestion. Sinha et al. 2018 showed liposomal glutathione raised blood glutathione and NK cell function over 6 months. More expensive than NAC; arguably worth the cost when NAC produces side effects or for severe depletion states.
  4. S-acetyl-glutathione — the acetyl group protects the thiol from oxidation during digestion. Limited but suggestive evidence for improved bioavailability over conventional glutathione. Still more expensive than NAC for unclear added benefit.
  5. Whey protein (10-40 g/day) — rich in cysteine-containing peptides (especially undenatured whey, preserving the disulfide bonds). Multiple studies show measurable increases in lymphocyte glutathione.
  6. Intravenous glutathione (600-2400 mg per session) — bypasses absorption entirely. Used investigationally for Parkinson's disease (Sechi 1996 showed symptomatic improvement); also used in some integrative-medicine practices for autoimmune and chronic infection. Studies are small; insurance does not cover.
  7. Sulforaphane (10-40 mg/day from broccoli sprout extract) — activates Nrf2, which transcribes the GCLC and GCLM genes that produce gamma-glutamyl cysteine ligase, increasing endogenous synthesis capacity. Indirect but durable mechanism.
  8. Alpha-lipoic acid (300-600 mg/day) — regenerates oxidized glutathione and other antioxidants. Also chelates metal ions that catalyze ROS production.

Back to Table of Contents

Conditions Associated with Glutathione Depletion

Glutathione depletion is documented in essentially every chronic disease state that has been studied. The relevant clinical contexts where repletion is likely to provide benefit:

Back to Table of Contents

Lab Testing for Glutathione Status

Several lab tests can characterize glutathione status, in order of clinical utility:

Most commercial labs (Quest, LabCorp) offer erythrocyte glutathione as a send-out test. Functional / specialty labs (Genova, Doctor's Data) offer the GSH/GSSG ratio and oxidative stress marker panels.

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Meister A, Anderson ME (1983). Glutathione. Annual Review of Biochemistry. — PubMed
  2. Lu SC (2013). Glutathione synthesis. Biochimica et Biophysica Acta. — PubMed
  3. Sekhar RV et al. (2011). Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. American Journal of Clinical Nutrition. — PubMed
  4. Kumar P et al. (2021). GlyNAC supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, body composition, and physical function. Clinical and Translational Medicine. — PubMed
  5. Sinha R et al. (2018). Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. European Journal of Clinical Nutrition. — PubMed
  6. Allen J, Bradley RD (2011). Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. JACM. — PubMed
  7. Richie JP Jr et al. (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. — PubMed
  8. Sechi G et al. (1996). Reduced intravenous glutathione in the treatment of early Parkinson's disease. Progress in Neuropsychopharmacology. — PubMed
  9. Prescott LF et al. (1979). Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. BMJ. — PubMed
  10. Forman HJ, Zhang H, Rinna A (2009). Glutathione: overview of its protective roles, measurement, and biosynthesis. Molecular Aspects of Medicine. — PubMed
  11. Townsend DM, Tew KD, Tapiero H (2003). The importance of glutathione in human disease. Biomedicine & Pharmacotherapy. — PubMed
  12. Schmitt B et al. (2015). Effects of N-acetylcysteine, oral glutathione (GSH), and a novel sublingual GSH formulation on functional and clinical outcomes in older subjects. Free Radical Biology & Medicine. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents